TY - EJOU
AU - LI, NINGYU
AU - CHEN, XIAOFANG
AU - GENG, SUXIA
AU - LAI, PEILONG
AU - HUANG, LISI
AU - LI, MINMING
AU - HUANG, XIN
AU - DENG, CHENGXIN
AU - WANG, YULIAN
AU - WENG, JIANYU
AU - DU, XIN
TI - miR-103-3p regulates the differentiation of bone marrow mesenchymal stem cells in myelodysplastic syndrome
T2 - BIOCELL
PY - 2023
VL - 47
IS - 1
SN - 1667-5746
AB - The pathogenesis of myelodysplastic syndrome (MDS) may be related to the abnormal expression of microRNAs
(miRNAs), which could influence the differentiation capacity of mesenchymal stem cells (MSCs) towards adipogenic and
osteogenic lineages. In this study, exosomes from bone marrow plasma were successfully extracted and identified.
Assessment of miR-103-3p expression in exosomes isolated from BM in 34 MDS patients and 10 controls revealed its
0.52-fold downregulation in patients with MDS compared with controls (NOR) and was downregulated 0.55-fold in
MDS-MSCs compared with NOR-MSCs. Transfection of MDS-MSCs with the miR-103-3p mimic improved osteogenic
differentiation and decreased adipogenic differentiation in vitro, while inhibition of miR-103-3p showed the opposite
results in NOR-MSCs. Thus, the expression of miR-103-3p decreases in MDS BM plasma and MDS-MSCs, significantly
impacting MDS-MSCs differentiation. The miR-103-3p mimics may boost MDS-MSCs osteogenic differentiation while
weakening lipid differentiation, thereby providing possible target for the treatment of MDS pathogenesis.
KW - Myelodysplastic syndrome
KW - Mesenchymal stem cells
KW - miR-103-3p
KW - Osteogenic differentiation
KW - Adipogenic differentiation
DO - 10.32604/biocell.2022.022021